Ryan joins Magenta from Foundation Medicine, where he served as chief financial officer.
During his tenure at Foundation, Ryan helped lead the company from early stage proof of concept to a global commercial organisation.
He was responsible for long-range planning and capital formation, and he played a key role in the company's relationship with, and sale to, Roche in July 2018.
Ryan also worked closely with the company's commercial leadership through several product launches and was deeply involved in Medicare and commercial payer reimbursement strategy and execution.
Prior to that, Ryan held management positions for Taligen Therapeutics, Codon Devices and Genomics Collaborative, and began his career at Deloitte and Touche. Ryan holds a B.S. in economics from Bates College and an M.B.A. from Babson College.
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca